Trusted by:
New potential therapeutic targets have been identified for diabetic kidney disease (DKD) - the leading cause of kidney failure in the world - that could see patients treated with new gene and drug therapies preventing the disease’s progression into end stage kidney failure.
With one IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the amount of blood the heart can pump and dramatically improves survival.
Quitline coaching over the phone helped almost half of young people who vape ditch the habit, potentially improving their health and decreasing the chances they’ll transition to cigarettes, according to a new Ohio State study.
A majority of U.S. adults hope to avoid political discussions during the holidays and, in some cases, family members they disagree with, according to a survey by the American Psychological Association.
Smokers with myelodysplastic syndromes or a precursor condition had elevated levels of genetic mutations linked to the disease. The study also found that heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.
Patients with multiple myeloma are living longer thanks to a host of new immunotherapies and targeted drugs. But there is still no cure for the disease. Physician-scientists at Sylvester Comprehensive Cancer Center are working to change that, and will present research findings at the 2024 annual meeting of the American Society of Hematology (ASH).
Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.
About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.
As the school year winds up, thousands of Aussie kids are looking forward to the summer holidays. But hand-in hand with this freedom comes an abundance of screentime, unhealthy snacks, and a lack of routine, and it has the potential to affect children’s physical and mental health.
A study sheds new light on how Toxoplasma gondii parasites make the proteins they need to enter a dormant stage that allows them to escape drug treatment.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right